Events and Presentations Events and Presentations Past Events SVB Securities Global Biopharma Conference Feb 15, 2023 at 1:40 PM EST Listen to webcast Supporting Materials View Presentation 4.9 MB Bank of America Securities 2022 Biotech SMID Cap Conference (Virtual) Dec 8, 2022 at 3:20 PM EST Listen to webcast JMP Securities Hematology and Oncology Summit (Virtual) Dec 6, 2022 at 10:00 AM EST Listen to webcast Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Presentations March 2023 Corporate Presentation NextCure Trial in Progress Poster for NC525 at the 2022 ASH Annual Meeting SITC 2022 Poster- A phase 1/2, open-label, dose-escalation, safety, and tolerability study of NC762 in subjects with advanced or metastatic solid tumors SITC 2022 Poster - A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory or MSS/MSI-low ICI naïve advanced or metastatic solid tumors ASH 2021 – A Novel LAIR-1 Antibody Target Acute Myeloid Leukemia (AML) Stem Cells ASH 2021 – Siglec-15 is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia NextCure Virtual Oncology Pipeline Update Presentation SITC 2021 Oral Presentation: Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors SITC 2021 Poster - Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization SITC 2021 Poster - NC410, a fusion protein of LAIR-2 fused to human IgG1 Fc is safe and tolerable with evidence of immune modulation in subjects with advanced solid tumors H. C. Wainwright 23rd Annual Global Investment Conference Presentation 19th Annual Morgan Stanley Global Healthcare Conference Presentation JMP Securities Life Sciences Conference Presentation NC410 ASCO 2021 Poster BofA Securities 2021 Virtual Health Care Conference Presentation Truist Securities Life Sciences Summit Presentation Needham Healthcare Conference Presentation NC762 AACR 2021 Poster NextCure Virtual R&D Update Presentation NC410 (Tian) SITC 2020 Poster NC410 (Horn) SITC 2020 Poster NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting NextCure Presents Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of SITC NextCure Hosts and Webcast Event at the 34th Annual Meeting of SITC NextCure Presents Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting (PDF) Tools
Events and Presentations Past Events SVB Securities Global Biopharma Conference Feb 15, 2023 at 1:40 PM EST Listen to webcast Supporting Materials View Presentation 4.9 MB Bank of America Securities 2022 Biotech SMID Cap Conference (Virtual) Dec 8, 2022 at 3:20 PM EST Listen to webcast JMP Securities Hematology and Oncology Summit (Virtual) Dec 6, 2022 at 10:00 AM EST Listen to webcast Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Presentations March 2023 Corporate Presentation NextCure Trial in Progress Poster for NC525 at the 2022 ASH Annual Meeting SITC 2022 Poster- A phase 1/2, open-label, dose-escalation, safety, and tolerability study of NC762 in subjects with advanced or metastatic solid tumors SITC 2022 Poster - A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory or MSS/MSI-low ICI naïve advanced or metastatic solid tumors ASH 2021 – A Novel LAIR-1 Antibody Target Acute Myeloid Leukemia (AML) Stem Cells ASH 2021 – Siglec-15 is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia NextCure Virtual Oncology Pipeline Update Presentation SITC 2021 Oral Presentation: Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors SITC 2021 Poster - Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization SITC 2021 Poster - NC410, a fusion protein of LAIR-2 fused to human IgG1 Fc is safe and tolerable with evidence of immune modulation in subjects with advanced solid tumors H. C. Wainwright 23rd Annual Global Investment Conference Presentation 19th Annual Morgan Stanley Global Healthcare Conference Presentation JMP Securities Life Sciences Conference Presentation NC410 ASCO 2021 Poster BofA Securities 2021 Virtual Health Care Conference Presentation Truist Securities Life Sciences Summit Presentation Needham Healthcare Conference Presentation NC762 AACR 2021 Poster NextCure Virtual R&D Update Presentation NC410 (Tian) SITC 2020 Poster NC410 (Horn) SITC 2020 Poster NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting NextCure Presents Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of SITC NextCure Hosts and Webcast Event at the 34th Annual Meeting of SITC NextCure Presents Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting (PDF)
SVB Securities Global Biopharma Conference Feb 15, 2023 at 1:40 PM EST Listen to webcast Supporting Materials View Presentation 4.9 MB
Bank of America Securities 2022 Biotech SMID Cap Conference (Virtual) Dec 8, 2022 at 3:20 PM EST Listen to webcast
JMP Securities Hematology and Oncology Summit (Virtual) Dec 6, 2022 at 10:00 AM EST Listen to webcast
SITC 2022 Poster- A phase 1/2, open-label, dose-escalation, safety, and tolerability study of NC762 in subjects with advanced or metastatic solid tumors
SITC 2022 Poster - A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory or MSS/MSI-low ICI naïve advanced or metastatic solid tumors
ASH 2021 – Siglec-15 is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia
SITC 2021 Oral Presentation: Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors
SITC 2021 Poster - Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization
SITC 2021 Poster - NC410, a fusion protein of LAIR-2 fused to human IgG1 Fc is safe and tolerable with evidence of immune modulation in subjects with advanced solid tumors
NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
NextCure Presents Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of SITC
NextCure Presents Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting (PDF)
